Amyloid-Targeting Therapies in Alzheimer Disease: Mechanisms of Action, Efficacy, and Safety Considerations

Panelists discuss how amyloid-targeting therapies for Alzheimer disease represent a breakthrough drug class that works by binding to and removing beta-amyloid plaques through various mechanisms, demonstrating modest cognitive decline reduction in clinical trials while presenting safety considerations including amyloid-related imaging abnormalities (ARIA), infusion reactions, and the need for careful patient selection and monitoring protocols.

EP: 1.Strategies for Enhancing Early Diagnosis and Implementation of Disease-Modifying Therapies in Alzheimer Disease

EP: 2.Advancing Early Alzheimer Diagnosis: Best Practices for Timely Screening and Detection

EP: 3.Care Pathways for Nonspecialist Providers When Evaluating Patients With Potential Mild Cognitive Impairment

EP: 4.Empowering Nonspecialist Providers and Addressing Gaps in Dementia Care: How Tools and Biomarkers Can Help

EP: 5.Factors to Evaluate When Selecting a Combination of Screening Assessments and Tests for Detecting Alzheimer Disease

EP: 6.From Time Constraints to Reimbursement: Addressing Key Hurdles in Cognitive Screening for Alzheimer Disease

EP: 7.Expanding Access to Alzheimer Disease Care: Leveraging Referral Networks and Telemedicine for Patients in Underserved Areas

Now Viewing

EP: 8.Amyloid-Targeting Therapies in Alzheimer Disease: Mechanisms of Action, Efficacy, and Safety Considerations

EP: 9.Real-World Implications of Changes in CDR-SB Score in Patients Receiving Amyloid-Targeting Therapy

Video content above is prompted by the following:

• Please discuss the class and complete drug profile of amyloid-targeting therapies for Alzheimer disease, including their mechanisms of action, efficacy, and safety profiles.

Related Videos

Related Content

Advertisement

April 3rd 2025

Radiation Bridging Therapy Boosts CAR T Outcomes in R/R LBCL

Maggie L. Shaw

In this comparative analysis, patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) received bridging therapy via radiation or systemic treatment while their chimeric antigen receptor T-cell therapy (CAR T) was being manufactured.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

April 3rd 2025

Obesity May Increase Surgical Complications in Epithelial Ovarian Cancer

Brooke McCormick

The most common surgical complications in obese patients with epithelial ovarian cancer (EOC) include wound infection, intestinal problems, and a higher 30-day readmission rate.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

April 3rd 2025

Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease

Julia Bonavitacola

The topical ocular drug is an investigational new drug candidate that requires more well-controlled studies to establish efficacy, according to the FDA.

April 1st 2025

MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe

Maggie L. Shaw

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.

Related Content

Advertisement

April 3rd 2025

Radiation Bridging Therapy Boosts CAR T Outcomes in R/R LBCL

Maggie L. Shaw

In this comparative analysis, patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) received bridging therapy via radiation or systemic treatment while their chimeric antigen receptor T-cell therapy (CAR T) was being manufactured.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

April 3rd 2025

Obesity May Increase Surgical Complications in Epithelial Ovarian Cancer

Brooke McCormick

The most common surgical complications in obese patients with epithelial ovarian cancer (EOC) include wound infection, intestinal problems, and a higher 30-day readmission rate.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

April 3rd 2025

Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease

Julia Bonavitacola

The topical ocular drug is an investigational new drug candidate that requires more well-controlled studies to establish efficacy, according to the FDA.

April 1st 2025

MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe

Maggie L. Shaw

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.